BMS and Otsuka Extend Abilify Partnership
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)
Published: 7 Apr-2009
DOI: 10.3833/pdr.v2009.i4.1088 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb is extending its partnership with Japan’s Otsuka Pharmaceuticals until 2015 on the US sales of their blockbuster psychiatric drug, Abilify® (aripiprazole)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
Login Problems
RSS